{
    "clinical_study": {
        "@rank": "33270", 
        "acronym": "PROMISS", 
        "arm_group": [
            {
                "arm_group_label": "High loading dose of rosuvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "rosuvastatin 20mg/d\u00d71w"
            }, 
            {
                "arm_group_label": "Routine rosuvastatin therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "rosuvastatin 10mg/d\u00d71w"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the effect of 20mg high loading dose of rosuvastatin\n      on recurrent events in patients with established DM who is admitted for an ACS."
        }, 
        "brief_title": "Peking and Rotterdam on Mission to Reduce Coronary Artery Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Men or women \u226540 years of age admitted with a clinical diagnosis of ACS. The\n             diagnosis should be based on the combination of typical ischemic chest complaints and\n             objective evidence of myocardial ischemia or myocardial necrosis as demonstrated by\n             the electrocardiogram (ECG) or elevated cardiac markers, as follows:\n\n          -  Typical ischemic chest pain, lasting 10 minutes or more, within the preceding 24\n             hours, AND either\n\n          -  ECG changes indicative of myocardial ischemia within 24 hours after the onset of\n             chest pain (ECG showing persistent or non-persistent ST-segment elevation >1.0 mm in\n             two or more contiguous leads or dynamic ST-segment depression >1.0 mm in two or more\n             contiguous leads) or\n\n          -  Elevated biomarkers of myocardial necrosis within 24 hours after the onset of chest\n             pain (i.e. CK-MB >1 times the upper limit of normal of the local laboratory, or\n             Troponin-T >0.1 ng/ml.\n\n               -  A diagnosis of DM type II prior to the index ACS\n\n               -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  \u2022 Myocardial ischemia precipitated by a condition other than atherosclerotic coronary\n             artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine,\n             severe valvular disease, hypotension).\n\n               -  Severely-impaired left ventricular function (ejection fraction <30%) or\n                  end-stage congestive heart failure NYHA-class III or IV (in order to avoid\n                  lost-to-follow-up due to non-acute coronary syndrome events).\n\n               -  Severe chronic kidney disease with measured or calculated glomerular filtration\n                  rate (Cockgroft-Gault or MDRD4 (Modification of Diet in Renal Disease) formula)\n                  of <30 ml/min/1.73m2, or renal dialysis.\n\n               -  Co-existent condition associated with a life-expectancy <12 months, or otherwise\n                  unlikely to appear at all scheduled follow-up visits.\n\n               -  Known serious or hypersensitivity reactions to HMG-CoA reductase inhibitors.\n\n               -  Triglyceride (TG) level \u2265500 mg/dL (5.65 mmol/L) at screening, because patients\n                  with very high triglyceride levels warrant treatment with agents that may\n                  increase the risk of side effects associated with statin drugs.\n\n               -  Active liver disease or hepatic dysfunction, as determined by alanine\n                  aminotransferase (ALT [SGPT]) >3 x ULN or bilirubin levels >1.5 x ULN at\n                  screening.\n\n               -  Myopathy.\n\n               -  Not using effective contraceptive methods.\n\n               -  Participation in any investigational drug study less than 30 days prior to\n                  enrolment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653119", 
            "org_study_id": "PUCRP-004"
        }, 
        "intervention": {
            "arm_group_label": [
                "High loading dose of rosuvastatin", 
                "Routine rosuvastatin therapy"
            ], 
            "description": "Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.", 
            "intervention_name": "Rosuvastatin", 
            "intervention_type": "Drug", 
            "other_name": "Crestor"
        }, 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute coronary syndrome", 
            "Diabetes mellitus", 
            "Statins", 
            "High loading dose", 
            "Recurrent events"
        ], 
        "lastchanged_date": "July 26, 2012", 
        "link": {
            "description": "PUCRI", 
            "url": "http://pucri.bjmu.edu.cn/en/Default.aspx"
        }, 
        "location": {
            "contact": {
                "email": "dr_gaowei@medmail.com.cn", 
                "last_name": "Wei Gao, Master", 
                "phone": "+8613901366179"
            }, 
            "contact_backup": {
                "email": "beate_vv@bjmu.edu.cn", 
                "last_name": "Wei Zhao, Doctor", 
                "phone": "+8618600017812"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100191"
                }, 
                "name": "Peking University Third Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Peking and Rotterdam on Mission to Reduce Coronary Artery Disease", 
        "other_outcome": {
            "measure": "The proportion of any AST or ALT >3 x ULN or CK >5 x ULN", 
            "safety_issue": "Yes", 
            "time_frame": "during the 1-year follow up period"
        }, 
        "overall_contact": {
            "email": "dr_gaowei@medmail.com.cn", 
            "last_name": "Wei Gao, Master", 
            "phone": "+8613901366179"
        }, 
        "overall_contact_backup": {
            "email": "beate_vv@bjmu.edu.cn", 
            "last_name": "Wei Zhao", 
            "phone": "+8618600017812"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS", 
            "safety_issue": "No", 
            "time_frame": "during 12 months follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653119"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University Third Hospital", 
            "investigator_full_name": "Wei Gao", 
            "investigator_title": "doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS", 
            "safety_issue": "No", 
            "time_frame": "during 30 days follow-up"
        }, 
        "source": "Peking University Third Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University Third Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }
}